Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Yanhong Deng, Chao Wang et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 304
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with <i>RAS</i>/<i>BRAF</i> Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Yanhong Deng, Kun Wang et al.|The Oncologist|2020Cited by 50
Application and comparison of different implanted ports in malignant tumor patientsYanhong Li, Yanhong Deng, Yonghua Cai et al.|World Journal of Surgical Oncology|2016Cited by 19
mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trialCailu Shen, Yanhong Deng, Huabin Hu et al.|Annals of Translational Medicine|2022Cited by 9